Crystallisation was never mentioned. The reason was based on a series of M&A's and nothing to do with inefficiencies of the drug.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-28
-
- There are more pages in this discussion • 364 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
0.070(4.61%) |
Mkt cap ! $274.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $52.62K | 33.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9571 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 2615 | 2 |
View Market Depth
| Last trade - 11.48am 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |